SURG vs. STIM, INFU, INGN, SGHT, NYXH, ELMD, CVRX, KRMD, CV, and MBOT
Should you be buying SurgePays stock or one of its competitors? The main competitors of SurgePays include Neuronetics (STIM), InfuSystem (INFU), Inogen (INGN), Sight Sciences (SGHT), Nyxoah (NYXH), Electromed (ELMD), CVRx (CVRX), KORU Medical Systems (KRMD), CapsoVision (CV), and Microbot Medical (MBOT). These companies are all part of the "medical equipment" industry.
SurgePays vs. Its Competitors
Neuronetics (NASDAQ:STIM) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.
Neuronetics presently has a consensus price target of $7.00, indicating a potential upside of 111.48%. SurgePays has a consensus price target of $9.00, indicating a potential upside of 232.10%. Given SurgePays' higher possible upside, analysts plainly believe SurgePays is more favorable than Neuronetics.
53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 6.9% of SurgePays shares are owned by institutional investors. 8.7% of Neuronetics shares are owned by insiders. Comparatively, 30.5% of SurgePays shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Neuronetics has higher revenue and earnings than SurgePays. Neuronetics is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.
Neuronetics has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, SurgePays has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.
In the previous week, Neuronetics had 1 more articles in the media than SurgePays. MarketBeat recorded 4 mentions for Neuronetics and 3 mentions for SurgePays. Neuronetics' average media sentiment score of 1.40 beat SurgePays' score of 0.04 indicating that Neuronetics is being referred to more favorably in the media.
Neuronetics has a net margin of -43.47% compared to SurgePays' net margin of -133.85%. Neuronetics' return on equity of -156.36% beat SurgePays' return on equity.
Summary
Neuronetics beats SurgePays on 11 of the 14 factors compared between the two stocks.
Get SurgePays News Delivered to You Automatically
Sign up to receive the latest news and ratings for SURG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SURG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SurgePays Competitors List
Related Companies and Tools
This page (NASDAQ:SURG) was last updated on 9/5/2025 by MarketBeat.com Staff
Free SURG Stock Alerts